Synopsis
Synopsis
0
KDMF
0
VMF
0
Europe
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Compazine
2. Edisylate Salt, Prochlorperazine
3. Edisylate, Prochlorperazine
4. Maleate, Prochlorperazine
5. Prochlorperazine
6. Prochlorperazine Edisylate
7. Prochlorperazine Edisylate Salt
8. Salt, Prochlorperazine Edisylate
1. Prochlorperazine Dimaleate
2. 84-02-6
3. Prochlorperazine Dimaleate Salt
4. Buccastem
5. Vertigon
6. I1t8o1jtl6
7. Proclorperazine Maleate
8. Prochlorperazinu Dimaleat
9. Prochlorperazine Bimaleate
10. Prochlorperazine Hydrogen Maleate
11. Prochloroproazine Hydrogen Maleate
12. 10h-phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-, (z)-2-butenedioate (1:2)
13. Dsstox_cid_28941
14. Dsstox_rid_83206
15. Dsstox_gsid_49015
16. Emetiral
17. Pasotomin
18. Nibromin A
19. Meterazin Maleate
20. 2-chloro-10-[3[(4-methyl-1-piperazinyl)propyl]-10h-phenothiazine Dimaleate
21. Chebi:8436
22. Stemetil Dimaleate
23. 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine Dimaleate
24. 2-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine, Dimaleate
25. 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine Maleate (1:2)
26. Cas-84-02-6
27. Sr-01000000260
28. Ncgc00015856-08
29. Mfcd00069330
30. Unii-i1t8o1jtl6
31. Prochlorperazine Maleate [jan]
32. Prochlorperazinu Dimaleat [czech]
33. Compazine (tn)
34. C20h24cln3s.2c4h4o4
35. Prestwick_410
36. Einecs 201-511-3
37. Prochlorperazine Maleate [usp:jan]
38. Prochlorperazin-dimaleat
39. Prochlorperazinedimaleate
40. 2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine Dimaleate
41. Prochlorperazine, Dimaleate
42. Schembl40755
43. Chembl1314751
44. Dtxsid1049015
45. Hms1569o19
46. Hms2096o19
47. Hms3263o09
48. Hms3713o19
49. Hms3885j12
50. Tox21_113522
51. Tox21_501034
52. S4631
53. Prochlorperazine Maleate (jp17/usp)
54. Akos024457528
55. Tox21_113522_1
56. Ccg-220399
57. Ccg-222338
58. Lp01034
59. Nsc 748866
60. Prochlorperazine Dimaleate [mi]
61. Prochlorperazine Maleate [mart.]
62. Prochlorperazine Maleate [vandf]
63. Ncgc00015856-10
64. Ncgc00094323-01
65. Ncgc00261719-01
66. Prochlorperazine Maleate [usp-rs]
67. Prochlorperazine Maleate [who-dd]
68. As-13744
69. Bp165885
70. Eu-0101034
71. P2368
72. Prochlorperazine Maleate [green Book]
73. Prochlorperazine Maleate [orange Book]
74. D00479
75. P 9178
76. Prochlorperazine Dimaleate [green Book]
77. Prochlorperazine Maleate [ep Monograph]
78. Prochlorperazine Maleate [usp Impurity]
79. Prochlorperazine Maleate [usp Monograph]
80. Sr-01000000260-2
81. Sr-01000000260-9
82. Q27108082
83. 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine Dimaleate
84. Prochlorperazine Maleate, British Pharmacopoeia (bp) Reference Standard
85. Prochlorperazine Maleate, European Pharmacopoeia (ep) Reference Standard
86. 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine Maleate (1:2).
87. 2-chloro-10-[3[(4-methyl-1-piperazi Nyl)propyl]-10h-phenothiazine Dimaleate
88. Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-, Maleate (1:2)
89. Prochlorperazine Maleate, United States Pharmacopeia (usp) Reference Standard
90. 10h-phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-, (2z)-2-butenedioate (1:2)
Molecular Weight | 606.1 g/mol |
---|---|
Molecular Formula | C28H32ClN3O8S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 8 |
Exact Mass | 605.1598639 g/mol |
Monoisotopic Mass | 605.1598639 g/mol |
Topological Polar Surface Area | 184 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 548 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 1 | |
---|---|
Drug Name | Prochlorperazine maleate |
Active Ingredient | Prochlorperazine maleate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Sandoz; Teva Pharms; Mylan |
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
60
PharmaCompass offers a list of Prochlorperazine Maleate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Prochlorperazine Maleate manufacturer or Prochlorperazine Maleate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Prochlorperazine Maleate manufacturer or Prochlorperazine Maleate supplier.
PharmaCompass also assists you with knowing the Prochlorperazine Maleate API Price utilized in the formulation of products. Prochlorperazine Maleate API Price is not always fixed or binding as the Prochlorperazine Maleate Price is obtained through a variety of data sources. The Prochlorperazine Maleate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DSSTox_CID_28941 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DSSTox_CID_28941, including repackagers and relabelers. The FDA regulates DSSTox_CID_28941 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DSSTox_CID_28941 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DSSTox_CID_28941 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DSSTox_CID_28941 supplier is an individual or a company that provides DSSTox_CID_28941 active pharmaceutical ingredient (API) or DSSTox_CID_28941 finished formulations upon request. The DSSTox_CID_28941 suppliers may include DSSTox_CID_28941 API manufacturers, exporters, distributors and traders.
click here to find a list of DSSTox_CID_28941 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DSSTox_CID_28941 DMF (Drug Master File) is a document detailing the whole manufacturing process of DSSTox_CID_28941 active pharmaceutical ingredient (API) in detail. Different forms of DSSTox_CID_28941 DMFs exist exist since differing nations have different regulations, such as DSSTox_CID_28941 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DSSTox_CID_28941 DMF submitted to regulatory agencies in the US is known as a USDMF. DSSTox_CID_28941 USDMF includes data on DSSTox_CID_28941's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DSSTox_CID_28941 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DSSTox_CID_28941 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DSSTox_CID_28941 Drug Master File in Japan (DSSTox_CID_28941 JDMF) empowers DSSTox_CID_28941 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DSSTox_CID_28941 JDMF during the approval evaluation for pharmaceutical products. At the time of DSSTox_CID_28941 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DSSTox_CID_28941 suppliers with JDMF on PharmaCompass.
A DSSTox_CID_28941 CEP of the European Pharmacopoeia monograph is often referred to as a DSSTox_CID_28941 Certificate of Suitability (COS). The purpose of a DSSTox_CID_28941 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DSSTox_CID_28941 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DSSTox_CID_28941 to their clients by showing that a DSSTox_CID_28941 CEP has been issued for it. The manufacturer submits a DSSTox_CID_28941 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DSSTox_CID_28941 CEP holder for the record. Additionally, the data presented in the DSSTox_CID_28941 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DSSTox_CID_28941 DMF.
A DSSTox_CID_28941 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DSSTox_CID_28941 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DSSTox_CID_28941 suppliers with CEP (COS) on PharmaCompass.
A DSSTox_CID_28941 written confirmation (DSSTox_CID_28941 WC) is an official document issued by a regulatory agency to a DSSTox_CID_28941 manufacturer, verifying that the manufacturing facility of a DSSTox_CID_28941 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DSSTox_CID_28941 APIs or DSSTox_CID_28941 finished pharmaceutical products to another nation, regulatory agencies frequently require a DSSTox_CID_28941 WC (written confirmation) as part of the regulatory process.
click here to find a list of DSSTox_CID_28941 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DSSTox_CID_28941 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DSSTox_CID_28941 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DSSTox_CID_28941 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DSSTox_CID_28941 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DSSTox_CID_28941 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DSSTox_CID_28941 suppliers with NDC on PharmaCompass.
DSSTox_CID_28941 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DSSTox_CID_28941 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DSSTox_CID_28941 GMP manufacturer or DSSTox_CID_28941 GMP API supplier for your needs.
A DSSTox_CID_28941 CoA (Certificate of Analysis) is a formal document that attests to DSSTox_CID_28941's compliance with DSSTox_CID_28941 specifications and serves as a tool for batch-level quality control.
DSSTox_CID_28941 CoA mostly includes findings from lab analyses of a specific batch. For each DSSTox_CID_28941 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DSSTox_CID_28941 may be tested according to a variety of international standards, such as European Pharmacopoeia (DSSTox_CID_28941 EP), DSSTox_CID_28941 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DSSTox_CID_28941 USP).